The EULAR data are the primary catalyst. If the late-breaking oral confirms the 71% ACR50 with deep B-cell depletion comparable to CAR T, the thesis of an 'off-the-shelf' alternative to CAR T in autoimmune indications strengthens materially. Monitor the webcast on June 8 and feedback from key opinion leaders. The Phase 3 initiation in 2026 is a major milestone derisking event, if the data are consistent, expect upward re-rating. Risk: interim small-sample data (31 patients) may not replicate in pivotal trials; competitive landscape with other NK and CAR T autoimmune programs.
ARTV drugs
ARTV drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+20- T+0 · May 20 $7.84entry
- T+1 · 6mo ago +1.91%α +1.72% · $7.99
- T+5 · 6mo ago −2.68%α −3.92% · $7.63
- T+20 · 5mo ago +25.26%α +24.51% · $9.82
- T+60 · due 3mo ago Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Artiva Biotherapeutics announced five data presentations at the EULAR 2026 Congress (June 3-6, 2026) for its AlloNK (AB-101) allogeneic NK cell therapy in autoimmune diseases. A late-breaking oral abstract showed 71% ACR50 response in refractory RA patients with ≥6-month follow-up, no relapses, and B-cell depletion comparable to autologous CD19 CAR T therapy. The company plans a Phase 3 registrational trial in refractory RA in 2026. This is a significant clinical data catalyst for a clinical-stage biotech, the data are early and interim but the CAR T comparability claim and refractory RA response rates are the key bullish signals.
Key Facts
- Five abstracts accepted at EULAR 2026, including one late-breaking oral presentation.
- Late-breaking abstract (LB0003): 71% ACR50 response in refractory RA patients with ≥6-month follow-up; zero relapses or new immunomodulatory agents required.
- First patient with severe Sjögren disease treated with AlloNK + rituximab showed positive experience (abstract OP0129).
- Data claim B-cell depletion comparable to autologous CD19 CAR T therapies (abstracts POS0355, AB0345).
- AlloNK is an allogeneic, off-the-shelf, non-genetically modified, cryopreserved NK cell therapy.
- Company plans to initiate a Phase 3 registrational trial in refractory RA in 2026.
- Live post-meeting webcast with KOL Dr. Paul Emery scheduled for June 8, 2026 at 8:15 am EDT.
- Market cap ~$228M, 92% analyst buy rating, $100M insider purchases in last 30 days.
Financial Impact
No financial data provided in press release. Artiva is pre-revenue clinical-stage (no revenue, no EPS). Market cap ~$228M. Insider purchases totalling $100M in 30 days signal strong confidence. If AlloNK progresses to approval in refractory RA (large market opportunity, RA biologics market >$25B globally), the value inflection is substantial.
Risk Factors
- Interim clinical data from 31 patients across trials, small sample, not randomized; results may not replicate in Phase 3.
- AlloNK is unapproved; regulatory path uncertain; safety/efficacy risks in larger populations.
- Competition from multiple CAR T and NK cell therapies in autoimmune indications (Kyverna, BMS, Fate, etc.).
- Cash runway not disclosed; dilutive financing possible as a clinical-stage company without revenue.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3297953 |
Track record
33 reports on ARTV
10 of 15 bullish or bearish reports moved the stock their way by T+20. Best: +66.32% at T+60 after the Jun 8, 2026 report. 16 of 18 went positive at some point.
Filters
- Nov 9, 20267d ago 8-K/A Bearish 7/10 Entry $4.06 Now $3.96 +2.46% settles Dec 9
- Nov 3, 202613d ago Insider Cluster Bearish 6/10 Entry $4.22 Now $3.96 +6.16% settles Dec 3
- Oct 27, 202620d ago 8-K Bearish 6/10 Entry $4.27 Now $3.96 +7.26% settles Nov 24
- Oct 6, 20265w ago 144 Neutral 3/10 Entry $7.00 to $4.21 Now $3.96 −43.43% ▼ −39.93% −38.69% vs SPY
- Sep 11, 20269w ago 8-K Neutral 3/10 Entry $10.14 to $6.77 Now $3.96 −60.95% ▼ −33.23% −35.50% vs SPY
- Sep 9, 20269w ago Insider Cluster Neutral 4/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
- Sep 9, 20269w ago Insider Cluster Neutral 3/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
- Sep 9, 20269w ago Insider Cluster Neutral 4/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
- Sep 9, 20269w ago Insider Cluster Neutral 3/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
- Sep 9, 20269w ago Insider Cluster Bearish 5/10 Entry $10.42 to $6.80 Now $3.96 +62.00% ▲ +34.74% +37.12% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers